癌症药物基因组学。
Cancer pharmacogenomics.
机构信息
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Epub 2011 Jul 27.
Abstract
Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.
摘要
药物基因组学研究正在产生分子诊断工具，可用于优化个体患者的药物选择和剂量。鉴于大多数抗癌药物的治疗指数较窄，以及治疗不足的严重后果，癌症化疗是将药物基因组学转化为临床应用的一个极有吸引力的治疗领域。本文讨论了遗传（种系）和获得性（体细胞）基因组变异源如何改变癌症化疗的毒性或疗效。
相似文献
1
Cancer pharmacogenomics.癌症药物基因组学。
Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Epub 2011 Jul 27.
2
Response to "personalized medicine, genomics, and pharmacogenomics".对“个性化医疗、基因组学和药物基因组学”的回应
Clin J Oncol Nurs. 2014 Dec;18(6):618. doi: 10.1188/14.CJON.618.
3
Precision in cancer pharmacogenomics.
Pharmacogenomics. 2020 Apr;21(5):311-316. doi: 10.2217/pgs-2020-0011. Epub 2020 Apr 3.
4
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities.精准肿瘤学：将基因组学和药物基因组学导向减少癌症不平等现象。
Cancer Cell. 2021 Jun 14;39(6):730-733. doi: 10.1016/j.ccell.2021.04.013. Epub 2021 May 20.
5
Pharmacogenetics and pharmacogenomics as tools in cancer therapy.药物遗传学和药物基因组学作为癌症治疗的工具。
Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042.
6
Application of pharmacogenomics in supportive oncology: a patient journey.药物基因组学在支持性肿瘤学中的应用：患者历程
Pharmacogenomics. 2022 Oct;23(15):807-811. doi: 10.2217/pgs-2022-0133. Epub 2022 Oct 14.
7
A Platform for Comprehensive Genomic Profiling in Human Cancers and Pharmacogenomics Therapy Selection.一个用于人类癌症综合基因组分析和药物基因组学治疗选择的平台。
Methods Mol Biol. 2018;1825:413-424. doi: 10.1007/978-1-4939-8639-2_14.
8
Clinical implementation of pharmacogenetics.药物遗传学的临床应用
Drug Metab Pers Ther. 2016 Mar;31(1):9-16. doi: 10.1515/dmpt-2015-0031.
9
New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics.癌症中针对种族的个性化医疗新视角：群体药物基因组学与药物计量学
Drug Metab Pers Ther. 2018 Jun 27;33(2):61-64. doi: 10.1515/dmpt-2018-0008.
10
Health: Make precision medicine work for cancer care.健康：让精准医疗在癌症治疗中发挥作用。
Nature. 2015 Apr 16;520(7547):290-1. doi: 10.1038/520290a.
引用本文的文献
1
Genomic signatures of selection in drug metabolizing genes across cattle populations.牛群中药物代谢基因选择的基因组特征。
Mamm Genome. 2025 Jun 17. doi: 10.1007/s00335-025-10139-7.
2
Germline variants in cancer therapy.癌症治疗中的种系变异
Cancer Drug Resist. 2019 Mar 19;2(1):18-30. doi: 10.20517/cdr.2019.05. eCollection 2019.
3
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.白血病和淋巴瘤中阿糖胞苷治疗的反应与毒性：从剂量难题到药物基因组生物标志物
Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966.
4
Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.铂类化疗的卵巢癌患者预测模型的改进：谷胱甘肽 S-转移酶活性谱的影响
Eur J Clin Pharmacol. 2016 May;72(5):545-53. doi: 10.1007/s00228-016-2015-3. Epub 2016 Jan 23.
5
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).参与癌症药物基因组学研究：对在癌症与白血病B组（联盟）注册参加临床试验的8456名患者的研究。
J Natl Cancer Inst. 2015 Jul 9;107(10). doi: 10.1093/jnci/djv188. Print 2015 Oct.
6
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.药物遗传学对急性淋巴细胞白血病治疗中反应和毒性的预测作用
Blood Rev. 2015 Jul;29(4):243-9. doi: 10.1016/j.blre.2015.01.001. Epub 2015 Jan 10.
7
Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.个性化测序与医学的未来：疾病的发现、诊断与攻克
Pharmacogenomics. 2014 Nov;15(14):1771-1790. doi: 10.2217/pgs.14.117.
8
Pharmacogenomics in oncology care.肿瘤护理中的药物基因组学。
Front Genet. 2014 Apr 8;5:73. doi: 10.3389/fgene.2014.00073. eCollection 2014.
9
Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.造血干细胞移植中的基因组飞跃：二代测序在造血细胞移植临床进展中的应用
Eur J Hum Genet. 2014 Jun;22(6):715-23. doi: 10.1038/ejhg.2013.247. Epub 2013 Nov 20.
10
Pharmacogenomics in early-phase clinical development.药物基因组学在早期临床开发中的应用。
Pharmacogenomics. 2013 Jul;14(9):1085-97. doi: 10.2217/pgs.13.81.
本文引用的文献
1
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.体细胞缺失调控 MSH2 蛋白稳定性的基因导致人白血病细胞中 DNA 错配修复缺陷和耐药性。
Nat Med. 2011 Sep 25;17(10):1298-303. doi: 10.1038/nm.2430.
2
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.他莫昔芬代谢物在雌激素受体上的活性水平，以及 I 期和 II 期酶的遗传多态性对其在血浆中浓度水平的影响。
Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30.
3
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.在接受辅助他莫昔芬治疗的早期乳腺癌患者中，功能显著的 CYP2D6 多态性与临床结局之间没有任何关联。
Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.
4
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.他莫昔芬代谢物浓度、CYP2D6 基因型与乳腺癌结局。
Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.
5
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.急性淋巴细胞白血病复发的遗传背景和药物基因组学。
Nat Genet. 2011 Mar;43(3):237-41. doi: 10.1038/ng.763. Epub 2011 Feb 6.
6
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.临床药物遗传学实施联盟噻嘌呤甲基转移酶基因型和巯嘌呤剂量指南。
Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.
7
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.CPIC：药物基因组学研究网络临床药物基因组学实施联盟。
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.
8
Pharmacogenomics in pediatric leukemia.儿科白血病的药物基因组学。
Curr Opin Pediatr. 2010 Dec;22(6):703-10. doi: 10.1097/MOP.0b013e32833fde85.
9
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.CYP2D6 多态性可预测他莫昔芬治疗的乳腺癌患者的预后：扩大多态性覆盖范围可改善风险分层。
Clin Cancer Res. 2010 Sep 1;16(17):4468-77. doi: 10.1158/1078-0432.CCR-10-0478. Epub 2010 Jun 1.
10
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.肌苷三磷酸焦磷酸酶的遗传多态性影响巯嘌呤-S-甲基转移酶状态个体化治疗急性淋巴细胞白血病时的巯嘌呤代谢和毒性。
Expert Opin Drug Saf. 2010 Jan;9(1):23-37. doi: 10.1517/14740330903426151.
Zotero 插件